Kristen Quigley
Chief Operating Officer at MOLECULAR TEMPLATES, INC.
Kristen Quigley active positions
Companies | Position | Start | End |
---|---|---|---|
MOLECULAR TEMPLATES, INC. | Chief Operating Officer | 2023-08-01 | - |
Corporate Officer/Principal | 2016-12-31 | 2023-08-01 |
Career history of Kristen Quigley
Former positions of Kristen Quigley
Companies | Position | Start | End |
---|---|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Chief Operating Officer | - | - |
Training of Kristen Quigley
Washington University in St. Louis | Undergraduate Degree |
Statistics
International
United States | 4 |
Operational
Chief Operating Officer | 2 |
Undergraduate Degree | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Private companies | 1 |
---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Stock Market
- Insiders
- Kristen Quigley
- Experience